Whalesbook
US Ki New Trade Policy: Pharma Industry Mein Halchal
US ne pharma sector mein ek bada kadam uthaya hai, jahan unhone kuch patented drugs ke imports par 100% tak ka tariff laga diya hai. Yeh decision national security ke reason se liya gaya hai, kyunki US foreign drug supply par apni reliance kam karna chahta hai.
India Ke Liye Kya Hai Raahat?
Iss tariff ka India par immediate impact kaafi kam hone ki umeed hai. Global Trade Research Initiative (GTRI) ke according, India America ke drug market ka 90% se zyada share generic medicines se rakhta hai. Iss wajah se, companies ko filhaal is tariff se bachaya gaya hai, ta-kareeb ek saal tak drug shortages aur price hike ko rokne ke liye.
US Ka Strategy Aur Future Uncertainty
Yeh tariffs US ki badhti hui protectionist trade policy ka hissa hai. Iska maksad drug companies ko US mein manufacturing wapas lane ke liye push karna hai. Supreme Court ke ek decision ke baad, US apni trade policy mein zyada assertive ho gaya hai. Iska matlab hai ki future mein India jaisi countries ko bhi mushkil ho sakti hai. Agar yeh tariffs generics par bhi lag gaye toh India ke pharma sector ke liye yeh significant risk ban jayega, jahan 2025 mein pharma exports $9.7 billion the, jo total exports ka 38% tha.
Global Market Par Asar Aur India Ka Past Experience
Jahan India ke generics filhaal safe hain, wahi Ireland, Switzerland, Germany jaise countries jo patented drugs export karte hain, un par pressure badhega. European Union ne 2023 mein US ko €92 billion ke pharma products export kiye the. History dekhein toh US tariffs ne pehle bhi Indian exports ko impact kiya hai. May aur September 2025 ke beech, India ke total US exports 37.5% gir gaye the, aur pharma exports 15.7% kam hue the duty badhne ke karan. Aise tariffs announcement ke baad Indian pharma stocks mein sharp giravat aai thi.
Long-Term Risk For India
GTRI founder Ajay Srivastava ka kehna hai ki jo Indian firms patented drugs ke inputs banati hain, un par bhi tariff lag sakta hai. 'Generics exempt for now' ka matlab hai ki ek saal baad review mein tariffs badh sakte hain. Experts ka yeh bhi kehna hai ki tariffs low-margin generics ke liye manufacturing wapas lane ka effective tareeka nahi hai, aur isse companies market chhod sakti hain jisse drug shortages ho sakti hain. Even trade deals hone ke baad bhi, US apni supply chains control karne par focus kar raha hai.
Pharma Trade Ka Naya Daur
Yeh tariffs global pharma trade mein ek 'turning point' maane ja rahe hain, jahan geopolitics ka role badh raha hai. Analysts warn kar rahe hain ki filhaal India ke generic exports ko direct nuksaan na ho, par badhti protectionism ek bada challenge rahegi. Indian pharma companies ko future policy changes ko closely monitor karna hoga.